Amifostine for Multiple Myeloma with Dr. William Bensinger
Dr. William Bensinger shares the results of a clinical study that was presented at the 54th ASH Annual Meeting and Exposition. For some time, Dr. Bensinger has been interested in the use of amifostine, a drug which has been around for over 35 years and has been used to help protect patients from the toxicity of various treatments. Dr. Bensinger wanted to find out if amifostine could help protect patients from the toxicity of higher-dose melphalan treatments. The study found that who took amfostine were able to tolerate the higher doses of melphalan and also experience a higher response rate than those who took just the standard dose of melphalan.
Therapies for Myeloma Patients After Relapse with Dr. William Bensinger
Dr. William Bensinger discusses therapies to treat multiple myeloma after relapse with Andrew Schorr from Patient Power at the American Society of Hematology (ASH) annual meeting in 2012. Dr. Bensinger talks about the controversial role of allogeneic transplants to treat myeloma patients. He also discusses drugs, such as lenalidomide, that have shown promising results for relapse patients.
Dr. Edward Libby at ASH 2013
Dr. Edward Libby provides an update on multiple myeloma treatment at ASH 2013. Dr. Libby is most excited about the research that's going into monoclonal antibodies for treatment of multiple myeloma. Monoclonal antibodies are relatively non-toxic, but have added to the quality of response in treatment of other diseases such as lymphoma. New trials are being conducted with Daratumumab in combination with Revlimid and Dexamethasone, with remarkable results for patients with relapsed and refractory multiple myeloma. Our understanding of smoldering myeloma is rapidly increasing, and positive results have been seen from beginning treatment at this earlier stage. However, Dr. Libby cautions that there is still much to learn and treatment of smoldering myeloma is not ready for the general world of oncology.